These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22809838)

  • 21. Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins.
    Boeckx C; Op de Beeck K; Wouters A; Deschoolmeester V; Limame R; Zwaenepoel K; Specenier P; Pauwels P; Vermorken JB; Peeters M; Van Camp G; Baay M; Lardon F
    Cancer Lett; 2014 Nov; 354(2):365-77. PubMed ID: 25192874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K
    Braig F; Kriegs M; Voigtlaender M; Habel B; Grob T; Biskup K; Blanchard V; Sack M; Thalhammer A; Ben Batalla I; Braren I; Laban S; Danielczyk A; Goletz S; Jakubowicz E; Märkl B; Trepel M; Knecht R; Riecken K; Fehse B; Loges S; Bokemeyer C; Binder M
    Cancer Res; 2017 Mar; 77(5):1188-1199. PubMed ID: 28031227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab.
    Li X; Lu Y; Lu H; Luo J; Hong Y; Fan Z
    Oncotarget; 2015 May; 6(13):11507-18. PubMed ID: 25871473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibody cetuximab impairs matrix metalloproteinases 2 and 9, epithelial-mesenchymal transition and cell migration in feline oral squamous cell carcinoma in vitro.
    Altamura G; Martano M; Matrone A; Corteggio A; Borzacchiello G
    Vet Comp Oncol; 2024 Mar; 22(1):149-155. PubMed ID: 38030131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
    Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
    J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab.
    Luo J; Hong Y; Lu Y; Qiu S; Chaganty BK; Zhang L; Wang X; Li Q; Fan Z
    Cancer Lett; 2017 Jan; 384():39-49. PubMed ID: 27693630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reciprocal activation of cancer-associated fibroblasts and oral squamous carcinoma cells through CXCL1.
    Wei LY; Lee JJ; Yeh CY; Yang CJ; Kok SH; Ko JY; Tsai FC; Chia JS
    Oral Oncol; 2019 Jan; 88():115-123. PubMed ID: 30616781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
    Fletcher EV; Love-Homan L; Sobhakumari A; Feddersen CR; Koch AT; Goel A; Simons AL
    Mol Cancer Res; 2013 Dec; 11(12):1574-84. PubMed ID: 24048704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line.
    Mriouah J; Boura C; Pinel S; Chretien AS; Fifre A; Merlin JL; Faivre B
    Int J Oncol; 2010 Dec; 37(6):1555-63. PubMed ID: 21042725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
    Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
    Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
    Jedlinski A; Ansell A; Johansson AC; Roberg K
    J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma.
    Chen SF; Nieh S; Jao SW; Wu MZ; Liu CL; Chang YC; Lin YS
    J Pathol; 2013 Oct; 231(2):180-9. PubMed ID: 23775566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.
    Bhola NE; Freilino ML; Joyce SC; Sen M; Thomas SM; Sahu A; Cassell A; Chen CS; Grandis JR
    Mol Cancer Ther; 2012 Jun; 11(6):1236-46. PubMed ID: 22491800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
    Li C; Iida M; Dunn EF; Wheeler DL
    Radiother Oncol; 2010 Nov; 97(2):330-7. PubMed ID: 20667610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.
    Rebucci M; Peixoto P; Dewitte A; Wattez N; De Nuncques MA; Rezvoy N; Vautravers-Dewas C; Buisine MP; Guerin E; Peyrat JP; Lartigau E; Lansiaux A
    Int J Oncol; 2011 Jan; 38(1):189-200. PubMed ID: 21109940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment.
    La Fleur L; Johansson AC; Roberg K
    PLoS One; 2012; 7(9):e44071. PubMed ID: 23049743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells.
    Saki M; Toulany M; Rodemann HP
    Radiother Oncol; 2013 Sep; 108(3):473-8. PubMed ID: 23891090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer.
    Schmitz S; Bindea G; Albu RI; Mlecnik B; Machiels JP
    Oncotarget; 2015 Oct; 6(33):34288-99. PubMed ID: 26437222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
    Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
    Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.